Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, is pleased to announce the appointment of
Ellen joins the Juvenescence team as the CEO of the Epigenetics Division of Juvenescence and CEO of our portfolio company, Souvien Bio Ltd, a biotechnology company focused on developing novel therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration. Most recently the CEO for Modus Therapeutics AB, Ellen brings a strong background in neuroscience to the company from her prior leadership positions at Pfizer, spanning neuroscience research and development. Ellen has a PhD in Pharmacology & Neuroscience from Yale University School of Medicine and worked in management consulting at SVB Leerink before moving into the industry.
Dr. Li-Huei Tsai and Dr. Stephen Haggarty said: “Ellen Donnelly is a wonderful addition to Souvien. We look forward to working with her to bring drugs targeting epigenetic mechanisms into human trials.”
ABOUT JUVENESCENCE LTD.
Juvenescence Limited is a life sciences company developing therapies to modify aging and increase healthy human longevity. It was founded by
Link to the BusinessWire press release found here.